Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 21.35 CHF -3.61% Market Closed
Market Cap: 802.2m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Gross Margin
Kuros Biosciences AG

79.1%
Current
74%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.1%
=
Gross Profit
41.6m
/
Revenue
52.5m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CH
Kuros Biosciences AG
SIX:KURN
790.5m CHF
79%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
311.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
139.5B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.6B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
136.8B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.5B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
35.7B EUR
89%
Country CH
Market Cap 790.5m CHF
Gross Margin
79%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 311.2B USD
Gross Margin
67%
Country US
Market Cap 139.5B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 103.6B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 136.8B AUD
Gross Margin
52%
Country US
Market Cap 77.5B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.7B EUR
Gross Margin
89%
No Stocks Found

Kuros Biosciences AG
Glance View

Market Cap
785m CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
5.85 CHF
Overvaluation 73%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.1%
=
Gross Profit
41.6m
/
Revenue
52.5m
What is the Gross Margin of Kuros Biosciences AG?

Based on Kuros Biosciences AG's most recent financial statements, the company has Gross Margin of 79.1%.